Tech Company Financing Transactions
Melt Pharmaceuticals Funding Round
Melt Pharmaceuticals closed a $24 million Series B financing round on 4/2/2024. Investors included private investors.
Transaction Overview
Company Name
Announced On
4/2/2024
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the further development of MELT-300, including the MELT-300 Phase 3 program.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5511 Virginia Way 300
Brentwood, TN 37027
USA
Brentwood, TN 37027
USA
Phone
Website
Email Address
Overview
Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of patented non-intravenous and non-opioid sedation and analgesia medicines for short-duration medical procedures in outpatient and in-office settings.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Larry Dillaha
Chief Financial Officer
Brad Osborne
VP - Operations
Giovanni De Castro
Browse more venture capital transactions:
Prev: 4/2/2024: Moongate venture capital transaction
Next: 4/2/2024: Stippl venture capital transaction
Share this article
Where The Data Comes From
We record funding rounds that are announced publicly. VC transactions reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs